File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Conference Paper: Prevalence of chemotherapy use and its impact on overall survival in patients with bone and soft tissue sarcomas: A population-based analysis of 3746 patients

TitlePrevalence of chemotherapy use and its impact on overall survival in patients with bone and soft tissue sarcomas: A population-based analysis of 3746 patients
Authors
Issue Date2019
PublisherOxford University Press. The Journal's web site is located at http://annonc.oxfordjournals.org/
Citation
The 44th European Society for Medical Oncology (ESMO) Congress (ESMO 2019), Barcelona, Spain, 27 September – 1 October 2019. Abstract Book In Annals of Oncology, 2019, v. 30 n. Suppl. 5, p. 691, article no. 1684P How to Cite?
AbstractBackground: The aims of this study were to understand the prevalence of chemotherapy (chemo) use and its associated impact on survival in patients (pts) with either bone- and soft-tissue sarcomas (STS) through a large real-world population dataset. Methods: A population-based retrospective database was assembled to extract pts with sarcoma, as defined as ICD-9-CM codes of bone (170.x) or/and soft tissue (171.x) who have attended clinics or hospitals of the Hong Kong Hospital Authority (HA) between Jan 2004 and Mar 2018. Eligible pts with index presentation of bone or/and soft tissue sarcoma (STS) on or after Jan 2005 were analysed to allow 1-year window. Drug dispensing records of chemotherapy drugs (chemo) from the HA as categorized by the British National Formulary 8.x were extracted and correlated with all-cause and cancer specific mortality. Results: Of 3746 pts identified, 3358 pts satisfied eligibility: bone: n = 661, STS n = 2576, both n = 121. 32.8% of pts (n = 1100) had chemo prescribed during the study period. The proportional use of chemo decreased with advancing age (<18y: 70.9%; 18-<40y: 42.2%; 40-65y: 36.1%, 65-80y: 19.7%;.>/=80y: 8.1%). Anthracyclines (AN) were the most commonly used class of chemo (19.8%), followed by alkylating drugs (17.3%), antimetabolites (11.9%) and vinca alkaloids & etoposide (8.7%). Comparing with pts who have not received chemo within the study period, the risk for death was higher in pts who have received AN either as first chemo (HR 1.51, 95%CI1.25-1.83; p < 0.001) or later lines of therapy (HR 1.55; 95%CI1.10-2.17; p = 0.002), and in pts who have had chemo but never received AN (HR 1.51; 95%CI1.27-1.80; p < 0.001). AN use resulted in significant reduction in mortality over non-AN chemo use if used within 3months of index diagnosis. This significance was not apparent in pts who started chemo >3months post diagnosis (log-rank p < 0.01 and p = 0.14 respectively). The impact of chemo on mortality reduction appeared greater in pts with bone- vs. STS. Conclusions: This is one of the largest assembled population-based real-world sarcoma cohort. Chemo use and choice of chemo has implications on survival. The positive effect on survival was especially prominent in pts with bone sarcomas.
Persistent Identifierhttp://hdl.handle.net/10722/279029
ISSN
2017 Impact Factor: 13.93
2015 SCImago Journal Rankings: 4.362

 

DC FieldValueLanguage
dc.contributor.authorLoong, HHF-
dc.contributor.authorWong, CKH-
dc.contributor.authorHo, CW-
dc.contributor.authorLeung, LKS-
dc.contributor.authorTse, T-
dc.contributor.authorKwan, SS-
dc.contributor.authorLau, YM-
dc.date.accessioned2019-10-21T02:18:19Z-
dc.date.available2019-10-21T02:18:19Z-
dc.date.issued2019-
dc.identifier.citationThe 44th European Society for Medical Oncology (ESMO) Congress (ESMO 2019), Barcelona, Spain, 27 September – 1 October 2019. Abstract Book In Annals of Oncology, 2019, v. 30 n. Suppl. 5, p. 691, article no. 1684P-
dc.identifier.issn0923-7534-
dc.identifier.urihttp://hdl.handle.net/10722/279029-
dc.description.abstractBackground: The aims of this study were to understand the prevalence of chemotherapy (chemo) use and its associated impact on survival in patients (pts) with either bone- and soft-tissue sarcomas (STS) through a large real-world population dataset. Methods: A population-based retrospective database was assembled to extract pts with sarcoma, as defined as ICD-9-CM codes of bone (170.x) or/and soft tissue (171.x) who have attended clinics or hospitals of the Hong Kong Hospital Authority (HA) between Jan 2004 and Mar 2018. Eligible pts with index presentation of bone or/and soft tissue sarcoma (STS) on or after Jan 2005 were analysed to allow 1-year window. Drug dispensing records of chemotherapy drugs (chemo) from the HA as categorized by the British National Formulary 8.x were extracted and correlated with all-cause and cancer specific mortality. Results: Of 3746 pts identified, 3358 pts satisfied eligibility: bone: n = 661, STS n = 2576, both n = 121. 32.8% of pts (n = 1100) had chemo prescribed during the study period. The proportional use of chemo decreased with advancing age (<18y: 70.9%; 18-<40y: 42.2%; 40-65y: 36.1%, 65-80y: 19.7%;.>/=80y: 8.1%). Anthracyclines (AN) were the most commonly used class of chemo (19.8%), followed by alkylating drugs (17.3%), antimetabolites (11.9%) and vinca alkaloids & etoposide (8.7%). Comparing with pts who have not received chemo within the study period, the risk for death was higher in pts who have received AN either as first chemo (HR 1.51, 95%CI1.25-1.83; p < 0.001) or later lines of therapy (HR 1.55; 95%CI1.10-2.17; p = 0.002), and in pts who have had chemo but never received AN (HR 1.51; 95%CI1.27-1.80; p < 0.001). AN use resulted in significant reduction in mortality over non-AN chemo use if used within 3months of index diagnosis. This significance was not apparent in pts who started chemo >3months post diagnosis (log-rank p < 0.01 and p = 0.14 respectively). The impact of chemo on mortality reduction appeared greater in pts with bone- vs. STS. Conclusions: This is one of the largest assembled population-based real-world sarcoma cohort. Chemo use and choice of chemo has implications on survival. The positive effect on survival was especially prominent in pts with bone sarcomas.-
dc.languageeng-
dc.publisherOxford University Press. The Journal's web site is located at http://annonc.oxfordjournals.org/-
dc.relation.ispartofAnnals of Oncology-
dc.relation.ispartof44th European Society for Medical Oncology (ESMO) Congress (ESMO 2019)-
dc.titlePrevalence of chemotherapy use and its impact on overall survival in patients with bone and soft tissue sarcomas: A population-based analysis of 3746 patients-
dc.typeConference_Paper-
dc.identifier.emailWong, CKH: carlosho@hku.hk-
dc.identifier.emailHo, CW: hochuwa@hku.hk-
dc.identifier.authorityWong, CKH=rp01931-
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1093/annonc/mdz283.017-
dc.identifier.hkuros307304-
dc.identifier.volume30-
dc.identifier.issueSuppl. 5-
dc.identifier.spage691, article no. 1684P-
dc.identifier.epage691, article no. 1684P-
dc.publisher.placeUnited Kingdom-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats